Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed

BIOLOGICAL

Diphtheria and Tetanus Toxoids Adsorbed

BIOLOGICAL

Tetanus and Diphtheria Toxoids Adsorbed

DRUG

Bacteriophage phi X 174

DRUG

Aldesleukin

Trial Locations (14)

10016

Nyu Ny Nichd Crs, New York

10032

Columbia IMPAACT CRS, New York

13210

SUNY Upstate Med. Univ., Dept. of Peds., Syracuse

20060

Children's National Med. Ctr., ACTU, Washington D.C.

33161

Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami

33701

USF - Tampa NICHD CRS, Tampa

90033

Usc La Nichd Crs, Los Angeles

90801

Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach

701122699

Tulane/LSU Maternal/Child CRS, New Orleans

941430105

UCSF Pediatric AIDS CRS, San Francisco

Unknown

UCSD Maternal, Child, and Adolescent HIV CRS, San Diego

20010-2970

Children's National Med. Ctr. Washington DC NICHD CRS, Washington D.C.

021155724

HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston

009365067

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00006066 - Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems | Biotech Hunter | Biotech Hunter